# CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

> **NCT05094206** · PHASE1 · TERMINATED · sponsor: **Medical College of Wisconsin** · enrollment: 4 (actual)

## Conditions studied

- B-cell Non Hodgkin Lymphoma
- B-cell Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** 0.75x10^6 cells/kg CAR20.19.22 cells
- **BIOLOGICAL:** 1x10^6 cells/kg CAR20.19.22 cells
- **BIOLOGICAL:** 2.5x10^6 cells/kg CAR20.19.22 cells
- **BIOLOGICAL:** 5x10^6 cells/kg CAR20.19.22 cells
- **BIOLOGICAL:** Dose expansion: The maximum tolerated dose of CAR20.19.22 cells

## Key facts

- **NCT ID:** NCT05094206
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-30
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-01-29
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05094206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05094206, "CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05094206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*